Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
Epic: ACCP
News: Latest news
Web Site: Access Pharmaceuticals
Other Articles: 20-07-201015-07-201014-07-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 02, 11:00Baobab Resources identifies distinct ore domain at Tete’s South Zone

Baobab MD Ben James said the latest drilling results from the Tete project's South Zone characterise a distinct, higher mass recovery, ore domain.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Thursday September 02, 08:15Indonesia edges closer toward uranium mining and nuclear power

After nearly five decades of national debate on the issue, Indonesia's central government may finally be ready to develop a national nuclear policy, which may lead to domestic uranium mining.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 01:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Access Pharmaceuticals

Access Pharmaceuticals

Access Pharmaceuticals (ACCP:  OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients.  MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010.  ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic.  Thiarabine is in human trials for the treatment of leukemias and lymphomas.  Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.

CLICK HERE FOR FULL ANLAYSIS OF ACCESS PHARMACEUTICALS
Friday, December 04, 2009

Access Pharmaceuticals’ MuGard used to treat 2,000 cancer patients since launch in Europe

by Sergei Balashov company news image

Shares in Access Pharmaceuticals (OTCBB: ACCP)(“Access”) slipped back in trading this morning despite reporting yesterday that over  2,000 cancer patients have been treated with its novel rinse, MuGard, which targets oral mucositis - a debilitating side effect of radiation treatment and chemotherapy.


Access is seeking to establish the product as the treatment-of-choice to prevent and treat oral mucositis. MuGard has already secured CE mark certification in Europe and is approved by the FDA (Food and Drugs Administration) in the US, and is currently conducting pre-marketing activities ahead of its commercial launch in H1 2010 in the US.


Since MuGard’s launch in six European countries by partner SpePharm, which included the UK, Germany, Italy, Norway, Greece and Sweden, over 15,000 bottles of MuGard have been used by over 2,000 patients, including patients using the treatment prohylactically and those using it following the onset of oral mucositis. The company said the initial feedback reflected that MuGard was well acecepted by both patients and healthcare professionals both as a preventative and curative treatment for oral mucositis.


“Access is pleased with the early acceptance of MuGard as a preventative and curative treatment for oral mucositis; we hope to be able to leverage SpePharm's early experiences around its launch in Europe to jump start our efforts here throughout the remainder of the year and into 2010,” said President and Chief Executive of Access Pharmaceuticals, Jeffrey Davis.


SpePharm is currently gathering feedback from clinicians in the UK, Germany and Italy that are participating in a patient assessment project, expecting that out of a total of approximately 1,500 patients who will be given MuGard in this project, a consistent number of patient forms will be collected by year end, and the information will be quality checked for potential presentation at a scientific or medical conference or meeting in the first half of 2010.


MuGard’s introduction into several additional countries in Europe is anticipated over the next 12 to 18 months.
ChangeWave, a research network for institutional and private investors, stated in November that it expected to see cash flow “steadily ramp up on the coming quarters” as Mugard is fully commercialized.  ChangeWave’s Editor, Joshua Levine  also noted that the company’s pharmaceutical-type margins would “instantly” impact its financial situation.


Griffin Securities in New York also recently put some numbers to Access’ potential. In the broker’s most recent note, it placed a price target of $11.00 per share on Access, based on projected sales forecasts for MuGard, plus potential milestone payments related to the company’s additional pipeline drugs including: ProLindac, a DACH platinum drug in Phase II trials,  Thiarabine, an anti-inflammatory drug for arthritis, and Cobalamin, a nanopolymer delivery technology based on vitamin B12.

Griffin is forecasting revenues of $2 million FY 2009, rising to $12.6 million in 2010, $29.5 million in 2011, US$48.6 million in 2012 and US$101 million in 2013.  Earnings per share rise at an equally fast pace from a loss per share of 61 cents in 2009 to earnings per share of $1.09 in 2013.

AddThis Feed Button
Register here to be notified of future Access Pharmaceuticals articles.

Other Access Pharmaceuticals articles


Other Access Pharmaceuticals news

More news ►

Investors interested in Access Pharmaceuticals recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.